Amarantus Bioscience Holdings, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. The Company owns or has licenses to various product candidates in the biopharmaceutical healthcare industry. It has acquired the rights to the engineered skin substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by Companyâ€™s wholly owned subsidiary Cutanogen Corporation. The Companyâ€™s wholly owned subsidiary MANF Therapeutics, Inc. owns intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF Therapeutics, Inc. is developing MANF-based products as treatments for ophthalmological disorders.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-26	US$0.000001	-99.00%	1,136,017
26-10-23	US$0.000100	-98.75%	44,000

Delayed Quote OTC Markets

More quotes

Market Closed - OTC Markets 09:30:05 2026-10-26 EDT			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		0.00%	-

20-07-27	Todos Medical Ltd. (OTCPK:TOMD.F) completed the acquisition of remaining 80.01% stake in Breakthrough Diagnostics Inc. from Amarantus BioScience Holdings, Inc.	CI
20-01-29	Amarantus BioScience Holdings, Inc. acquired majority interest in Hempori, Inc. for $0.38 million.	CI

Market Cap	2.11M 1.89M 1.74M 1.58M 2.95M 201M 3M 20.79M 8.29M 105M 7.91M 7.75M 333M	P/E 2014	-2.06x	P/E 2015	-0.15x
Enterprise Value	5.07M 4.54M 4.19M 3.79M 7.09M 483M 7.21M 50.02M 19.95M 253M 19.04M 18.64M 801M	EV / Sales 2014	-	EV / Sales 2015	-
Free-Float	100%	Yield 2014 *	-	Yield 2015	-

20-07-27	Todos Medical Ltd. (OTCPK:TOMD.F) completed the acquisition of remaining 80.01% stake in Breakthrough Diagnostics Inc. from Amarantus BioScience Holdings, Inc.	CI
20-01-29	Amarantus BioScience Holdings, Inc. acquired majority interest in Hempori, Inc. for $0.38 million.	CI
20-01-02	Amarantus Completes Sublicense of ESS, MANF and Phenoguard to Emerald Organic Products	CI
19-11-21	Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary Manf Therapeutics	CI
19-10-24	Amarantus Bioscience Holdings, Inc. Enters into Agreement to License Diverse Therapeutics Portfolio to CBD-Focused Emerald Organic Products with Emerald Organic Growth, Inc	CI
19-10-23	Coeptis Pharmaceuticals, Inc. terminated the acquisition of Elto Pharma, Inc. from PsychoGenics Inc. and Amarantus BioScience Holdings, Inc..	CI
19-06-25	Amarantus Enters into Letter of Intent with the Alchemists Kitchen to Establish Joint Venture for Research and Commercialization of Hemp and Herbal Smokables for Addiction Treatment Including Smoking Cessation	CI
19-06-18	Amarantus BioScience Holdings, Inc. Announces Positive Pre-Clinical Data for Manf in Wolfram Syndrome	CI
19-05-28	Amarantus Hires Evolution Venture Partners To Evaluate Alternatives For Expansion Into Legal Hemp	CI
19-04-21	Todos Medical Ltd. (OTCPK:TOMD.F) exercised the option to acquire the remaining 80.01% stake in Breakthrough Diagnostics Inc. from Amarantus BioScience Holdings, Inc..	CI
19-01-11	Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries	CI
18-12-03	Todos Medical Ltd. Enters into Joint Venture Agreement with Amarantus to Develop Alzheimer’S Blood Diagnostic Lympro Test 2.0	CI
18-11-27	Coeptis Pharmaceuticals, Inc. entered into a binding agreement to acquire Elto Pharma, Inc. from PsychoGenics Inc. and Amarantus BioScience Holdings, Inc..	CI

21-11-18	Amarantus BioScience : Notification of Late Filing	PU
20-07-28	Amarantus BioScience : Todos Medical Completes Acquisition of Breakthrough Diagnostics, Gains Full Rights to the Alzheimer’s Blood Diagnostic LymPro™ Test from Amarantus	AQ
20-05-08	Emerald Organic Products : Restructures Joint Venture Agreement With Todos Medical by Entering Joint Collaboration Agreement	AQ
20-03-17	Amarantus BioScience : Todos Medical and 3DMed Enter Into Coronavirus (COVID-19) and Influenza A/B Testing Kit Distribution Agreement in US and Israel	AQ
20-02-06	Amarantus BioScience : Announces Subsidiary MANF Therapeutics Enters Into Material Transfer Agreement with Dyadic International	AQ

Amarantus BioScience Holdings, Inc. Stock

Stocks

AMBS

US02300U2050

Biotechnology & Medical Research

Valuation: Amarantus BioScience Holdings, Inc.

Chart: Amarantus BioScience Holdings, Inc.

Latest news: Amarantus BioScience Holdings, Inc.

Press Releases: Amarantus BioScience Holdings, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Amarantus BioScience Holdings, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 week	0		0
1 month	0		0.01
Current year	0		0.25
1 year	0		0.25
3 years	0		0.25
5 years	0		0.25
10 years	0		0.25

Director	Title	Age	Since
John Commissiong BRD	Director/Board Member	81	2008-01-13
Robert Harris BRD	Director/Board Member	81	2010-11-30

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AMARANTUS BIOSCIENCE HOLDINGS, INC.	-99.00%	0.00%	-	-	630
WUXI APPTEC CO., LTD.	+0.34%	+1.12%	+34.75%	+61.06%	64.14B
ARGENX SE	+0.98%	+2.68%	+12.25%	+82.98%	55.53B
LONZA GROUP AG	+1.75%	+2.01%	+13.30%	+103.69%	53.03B
IQVIA HOLDINGS INC.	-1.43%	-1.17%	+26.27%	+52.86%	45.99B
BEONE MEDICINES AG	-0.48%	-2.80%	+18.01%	+117.99%	42.45B
REVOLUTION MEDICINES, INC.	+0.82%	+1.37%	+227.94%	+922.41%	40.45B
CELLTRION, INC.	-0.26%	-2.57%	+12.55%	+45.18%	32.25B
GENMAB A/S	-2.07%	+42.73%	+103.77%	+88.74%	34.47B
WUXI BIOLOGICS (CAYMAN) INC.	-2.72%	-0.44%	+22.58%	-5.63%	24.23B
Average	-10.21%	+3.44%	+52.38%	+163.25%	39.25B
Weighted average by Cap.	-0.08%	+3.13%	+49.26%	+160.88%

	2014	2015
Net sales	-	-
Net income	-27.28M -24.43M -22.54M -20.4M -38.14M -2.6B -38.76M -269M -107M -1.36B -102M -100M -4.31B	-25.21M -22.58M -20.84M -18.85M -35.26M -2.4B -35.83M -249M -99.17M -1.26B -94.63M -92.61M -3.98B
Net Debt	-89K -79.72K -73.54K -66.55K -124K -8.48M -126K -877K -350K -4.44M -334K -327K -14.05M	2.96M 2.66M 2.45M 2.22M 4.15M 282M 4.21M 29.23M 11.66M 148M 11.13M 10.89M 468M